Back to Agenda
Innovative Direct-to-Patient Study Model to Capture PRO Instrument Validation Data for Submission to a Regulatory Authority
Session Chair(s)
April N. Naegeli, DrPH, MPH
Senior Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, United States
This session will discuss benefits and limitations associated with using a direct-to-patient model for observational research. In addition, we will present learnings from our experience using a direct-to-patient model for patient-reported outcome (PRO) instrument validation.
Learning Objective : Review the strategic approach to using an innovative research model for validating a patient-reported outcome measure; Evaluate benefits and limitations associated with implementing a novel direct-to-patient approach to conducting this type of observational study; Define advantages of integrating multiple technologies and rapidly implementing lessons learned to maintain patient engagement.
Speaker(s)
April N. Naegeli, DrPH, MPH
Senior Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, United States
Strategic Approach to Using an Innovative Research Model for Validating a Patient-Reported Outcome Measure
John Reites
Chief Executive Officer, THREAD, United States
Benefits and Limitations Associated With Implementing a Novel Direct-to-Patient Approach to Conducting a Validation Study
Brandon M. Wojtowicz
Project Manager, eResearch Technology, ERT, United States
Advantages of Integrating Multiple Technologies and Rapidly Implementing Lessons Learned to Maintain Patient Engagement
Have an account?